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NeuroprotectionSirtuins are a conserved family of NAD+-dependent class III lysine deacetylases, known to regulate longevity. In
mammals, the sirtuin family has seven members (SIRT1–7), which vary in enzymatic activity, subcellular distri-
bution and targets. Pharmacological and genetic modulation of SIRTs has been widely spread as a promising
approach to slow aging and neurodegenerative processes. Huntington's disease (HD) is a neurodegenerative dis-
order linked to expression of polyglutamine-expanded huntingtin (HTT) protein for which there is still no
disease-reversing treatment. Studies in different animalmodels provide convincing evidence that SIRT1 protects
both cellular and animalmodels frommutant HTT toxicity, however controversial resultswere recently reported.
Indeed, as a consequence of a variety of SIRT-activation pathways, either activation or inhibition of a speciﬁc SIRT
appears to be neuroprotective. Therefore, this review summarizes the recent progress and knowledge in sirtuins
(particularly SIRT1–3) and their implications for HD treatment.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Lysine (Lys, K) acetylation is a speedily reversible and controlled
post-translational covalentmodiﬁcation known to regulate the function
of several proteins that are involved in gene transcription, signal trans-
duction, cellular transport and metabolism. Accumulating evidences
indicate that acetylation rivals phosphorylation as a regulatory modiﬁ-
cation [1,2]. Among the enzymes that regulate protein acetylation is
the family of β-nicotinamide adenine dinucleotide (NAD+)-dependent
Lys deacetylases termed sirtuins (SIRTs). Mammalian sirtuins comprise
seven enzymes, SIRT1–7, which are functionally nonredundant ande; Atg5, autophagy protein 5;
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apoptosis [4], circadian rhythm [5] and metabolic regulation [6]. The
unique deacetylation reaction of sirtuins requires NAD+ cleavage, gener-
ating nicotinamide (NAM), -O-acetyl-ADP ribose and the deacetylated
substrate [7]. All sirtuins remove acyl groups, predominantly acetyl, but
also succinyl, malonyl, palmitoyl and lipoyl; of relevance, the presence
or absence of acyl groups on speciﬁc Lys residues in proteins can change
their function and subcellular localization [8]. Interestingly, the genera-
tion of NAM at high concentrations can bind and thereby feedback-
inhibit sirtuin's activity [9]. Although these enzymes are rather con-
served, their N- and C-terminus vary [10], allowing the interaction with
different substrates and distinct subcellular localizations. SIRTs 1, 6 and
7 are primarily nuclear proteins, SIRTs 3, 4 and 5 are imported into mito-
chondria, while SIRT2 is cytosolic [11] (Table 1). SIRTs 1, 2 and 3 have
strong deacetylase activity, whereas SIRTs 4, 5, 6 and 7 display weak
deacetylase activity [12].
There is growing evidence, although still controversial, that these
proteins may extend lifespan in numerous lower eukaryotes [13–16].
Calorie restriction (CR), which entails reduced calorie consumption
without malnutrition, increases yeast replicative lifespan and was pro-
posed to work through a Sir2 (SIRT1 ortholog)-dependent mechanism
[17]. However, whole body overexpression (OE) of SIRT1 does not affect
lifespan inmice [18]. Despite this, SIRT1was shown to promote healthy
aging by preventing age-associated neurodegeneration [19,20]. In
particular, Lys deacetylases modulators attenuate degeneration in eu-
karyotic cells, namely yeast, Caenorhabditis elegans, and Drosophila
models of polyglutamine (polyQ) toxicity [21–24]. Such is the case of
Huntington's disease (HD), a neurodegenerative disorder characterized
by degeneration of neurons in the striatum and, progressively, in the
Table 1
Diversity of human SIRTs, location and proposed role in HD.
MW Location Activity Effects in HD
N C 
N C 
N C 
N C 
N C 
N C 
N C 
120 
43 
28 
44 
SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7
35 
34 
37 
45 
Nucleus 
Cytosol
Cytosol
Mitochondria
Nucleus 
Mitochondria
Mitochondria
Nucleus 
Nucleus 
Deacetylase
Deacetylase
Deacetylase
Deacetylase
ADP-ribosyl
transferase
Deacetylase
Deacetylase
ADP-ribosyl
transferase
Lipoamidase
Unknown
Unknown
Unknown
Unknown
Neuroprotective
References 
Lombard et al., (2007) [137]
Fu et al., (2012) [134] 
Neuroprotective(?) 
Toxic Luthi-Carter et al., (2010) [124]Chopra et al., (2012) [23]
Jeong et al., (2011) [47]
Jiang et al., (2012) [66]
Smith etal., (2014) [59]
Jiang et al., (2014) [95]
747 aa
389 aa
399 aa
314 aa
310 aa
355 aa
400 aa
Laurent et al., (2013) [163]
(
Mathias et al., (2014) [161]
Nakagawa et al., (2009) [164]
Park et al., (2013) [165]
Liszt et al., (2005) [166]
Zhong et al., (2010) [162]
Ford et al., (2006) [167]
The SIRT family consists of seven proteins that have a highly conserved catalytic core domain. Nevertheless, these enzymes have varied enzymatic activities, subcellular locations and,
consequently, function. Although all SIRTs have been described as having deacetylase activity, SIRT4-6 have limited and speciﬁc deacetylase activity [162-164, 167]. To counteract this
deﬁcit, certain SIRTs exhibit other enzymatic activities such as ADP-ribosylation [166], lipoylation [161] or desuccinylation [165]. This diagram illustrates the catalytic core domain (in
violet), molecular weight (in kDa), cellular location, predominant enzymatic activity(ies) and the putative role of each SIRT in HD.
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(N39 associated with complete penetrance) within the coding region of
the HTT gene, that in turn leads to the expression of mutant huntingtin
(mHTT) throughout the human body [26]. Neuropathologically, HD
involves the formation of intranuclear inclusions, as well as, perinuclear
cytoplasmic inclusions containing truncated polyQ fragments [27].
Clinical symptoms are typically characterized by psychiatric instability,
uncontrolledmovements, progressiveweight loss and cognitive deﬁcits
leading to dementia, culminating in death 15–20 years after the mani-
festation of initial symptoms [28]. HD causes increasing disability over
the years and current treatments may alleviate symptoms, but are not
curative.
It is hypothesized that the polyQ expansion causes a gain of function,
resulting in abnormal protein-protein interaction that affects several
pathways [26]. Aberrant transcriptional regulation is one possible
mechanism of mHTT toxicity since the mutant protein interacts with
several transcriptional regulators (e.g. [29]). Organelle trafﬁcking [30],
metabolic function [31], calcium handling [32] and proteasome system
[33] are also altered in HD; moreover, mitochondrial dysfunction is a
common neurodegenerative mechanism in HD pathogenesis [34].
The hypothesis that mitochondrial dysfunction contributes to the pro-
gression of HD was ﬁrst reported when systemic administration of
3-nitropropionic acid (3-NP) and malonate (respectively selective irre-
versible and reversible inhibitors of succinate dehydrogenase, a com-
plex II component of the electron transport chain (ETC)), was shown
to accurately mimic the neuropathological and clinical features of HD
[35,36]. Concordantly, there are several mechanisms by which the mu-
tation can cause mitochondrial dysfunction. It can occur as a conse-
quence of a direct interaction of mHTT with the mitochondrial outer
membrane [32], by disruption of transcription of nuclear-encodedmito-
chondrial proteins, leading to defective mitochondrial biogenesis,
reduced trafﬁcking to synapses, decreased ATP production and/or
ETC impairment through decreased activity ofmitochondrial complexes
II/III [34].Of note, sirtuins have provided interesting insights into some of
these mechanisms, since their targets are linked to metabolic and sur-
vival signaling pathways, which led researchers to investigate their
role in HD pathogenesis. Although pioneer results were encouraging,
some recent evidences are inconsistent. In this reviewwe debate the re-
cent advances in sirtuins cellular activities and their implications for the
neuroprotective treatment of HD.
2. SIRT1 and HD
SIRT1 is the best-characterized sirtuin and probably themost impor-
tant sirtuin involved in epigenetic regulation, a central process for tran-
scription and metabolic control that is disrupted in HD [37]. Deletion of
SIRT1 affects nearly 10% of all deacetylation sites, most of which occur
on nuclear proteins, further affecting their enzymatic activities [38].
SIRT1 is predominantly nuclear, however it has both nuclear import
and export sequences and was found in cytosolic fractions of the
mouse brain [39]. SIRT1 mediates heterochromatin formation through
deacetylation of K26 on histone H1 [40], K9 on histone H3 and K16
on histone H4 [41]. Decreased genome-wide histone acetylation
was found in the striatum of R6/2 mice (a HD mouse model express-
ing the exon 1 of human HTT gene, with approximately 150 CAG re-
peats); and treatment with the histone deacetylase (HDAC) inhibitor
phenylbutyrate reversed transcriptional abnormalities of individual
genes [42], suggesting that SIRT modulators could also exert beneﬁcial
effects. In addition to histones, SIRT1 also deacetylates non-histone sub-
strates, such as transcription factors (p53, p65, forkhead box class O
subfamily (FOXO1 and FOXO3a), retinoic acid receptor beta (RARβ),
peroxisome proliferator-activated receptor gamma coactivator-1-
alpha (PGC-1α), and others), DNA repair proteins (thymine DNA
glycosylase, Ku70) and signaling factors such as AMP-activated protein
kinase (AMPK) [6,43] (Fig. 1). SIRT1 is ubiquitously expressed, but
is greatly enriched in the brain since embryogenesis until adult stage,
having a crucial role as energy metabolic regulator in neurons [44].
Fig. 1. Potential protective role of SIRT1 activation in HD. mHTT aggregates in the nucleus and directly interacts and inhibits SIRT1 activity, affecting multiple downstream targets such
as PGC-1α, FOXO3a and TORC–CREB complex, decreasing transcription of genes that modulate mitochondrial biogenesis (e.g. NRF2 and TFAM), antioxidant defense (e.g. SOD2) and
neurotrophic support (e.g. BDNF), respectively. Moreover, SIRT1 inhibition also blocks AMPK-dependent survival pathways. In the presence of lower (↓↓) μM doses of resveratrol,
SIRT1 is activated counteracting dysfunctional transcription and increasing neuronal survival. Importantly, similar neuroprotective effects may also occur in a SIRT1-independent way,
using higher (↑↑) μM doses of resveratrol. On the epigenetic level, SIRT1 represses p300-CBP complex, which is already affected by mHTT, leading to further transcription repression,
as depicted by the red crosses at the promoter. Abbreviations: ac, acetyl group; AMPK, AMP-activated protein kinase; CBP, CREB-binding protein; CREB, cAMP response element-binding
protein; FOXO3a, forkhead box O3a; mHTT, mutant huntingtin; p300, E1A binding protein; PGC-1α, proliferator-activated receptor gamma coactivator-1-alpha; SIRT1, sirtuin 1; TORC,
transducer of regulated CREB activity 1.
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appears to be important along the progression of neurodegenerative
disorders. In fact, SIRT1 has been described to have a relevant role in
lifespan extension in a variety of models, including in HD [13–15,46,
47]; nevertheless, Burnett et al. [16] cast doubt on the robustness of pre-
vious ﬁndings. The authors re-examined the reported effects of Sir2 OE
on survival and found that the use of appropriate controls abolished the
apparent effects in both C. elegans and Drosophila [16], concluding that
the studies of gene effects on aging are vulnerable to confounding
effects of genetic background. Still, the number of SIRT1 substrates
has been increasing, and its actions on substrates are known to play im-
portant roles in fundamental cellular processes impaired in many neu-
rodegenerative diseases, including amyotrophic lateral sclerosis [48],
Alzheimer's disease [49], Parkinson's disease [50] and HD [47,51].
The ﬁrst evidence about the putative beneﬁcial effects of SIRT1mod-
ulation in HD came out in 2005when Parker and collaborators reported
that both increased gene expression of Sir2 or treatment with resvera-
trol (RESV), a potent activator of SIRT1 in vitro, prevented early neuronal
dysfunction in a transgenic C. elegansmodel expressing an exon 1-like
N-terminal fragment with 128Q repeats [52]. Moreover, the authors
showed that RESV (in a lower μMrange) protected striatal neuronal cul-
tures isolated from the HdhQ111 knock-in mice model of HD against
polyQ-mediated cell death, probably through a SIRT1-related mecha-
nism [52]. In accordance, yeast expressing the ﬁrst 17 N-terminal
amino acids of HTT exon 1 containing 47Q, which harbors a mid-size
polyQ tract, showed aggravated aggregation upon deletion of Sir2
[53]. Similarly, ΔSir2 yeast cells expressing expanded 103Q showed
higher levels of oxidative stress [54], a cytotoxic mechanism resulting
from expression of mutant polyQ [55,56]. Also, in Htt(Q97)-transfected
mammalian cells, expression of SIRT1 prevented cell death throughdeacetylation of Ku70 at K539 and K542, two critical deacetylation
sites that inﬂuence Ku70-Bax binding, hindering the translocation of
Bax to mitochondria and leading to subsequent cell death [57]. Never-
theless, with regard to lifespan regulation inmammals or invertebrates,
such as C. elegans and Drosophila, the results are not always alike. In a
HD ﬂy model, Sir2 OE did not decrease the lethality caused by mHtt
[58], however, the complete loss of Sir2 was deleterious in both ﬂy
and worm models [52,59]. Interestingly, Sir2 activation increased neu-
ronal survival, but did not rescue the early death phenotype of mHtt-
challenged ﬂies, suggesting that longevity promoting strategies may
operate throughmechanisms that are independent from those that pro-
tect against neurodegeneration [58]. In contrast with the previous
results, Jeong et al. observed that SIRT1 OE signiﬁcantly extended the
survival of R6/2 mice in nearly 30 days [47].
Although there is not a consensus related to the role of SIRT1 in
slowing HD lethal phenotype, the majority of the published work sys-
temically describes beneﬁcial effects of SIRT1 activation in multiple
cellular pathways, which culminates in neuronal survival andmotor im-
provement. One of them is the enhancement of transcriptional activity,
since SIRT1 is primarily nuclear and deacetylates several transcription
factors and coactivators [60,61]. As described before in this review, tran-
scriptional activity is severely impaired in HD models [62–64]. Studies
on DNA microarrays detected changes in gene expression proﬁles in
R6/2mice at early stages, suggesting that changes in expression precede
the appearance of disease signs [64]. Remarkably, the N-terminal of
mHTT has some structural similarities to known transcription factors
that are directly or indirectly regulated by SIRT1 [38], namely CREB
(cAMP response element-binding), CBP (CREB binding protein) and
p53, which is probably the main cause for mHTT modulation of tran-
scription factor activity [65]. Additionally, mHTT intranuclear inclusions
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factors (e.g. [29]). Of relevance, mHTT also interacts with SIRT1 and
inhibits SIRT1 deacetylase activity, resulting in hyperacetylation of
SIRT1 substrates such as FOXO3a transcription factor, inhibiting its
pro-survival function (Fig. 1). Notably, the concentrations of acetylated
FOXO3awere signiﬁcantly increased in BACHDmice and in striatal cells
containing mHTT [66]. Nevertheless, SIRT1 OE counteracted mHTT-
induced deacetylase deﬁcit, restoring ATP levels in HD striatal-like
cells [66]. Additionally, SIRT1 OE in HDmouse models expressing trun-
cated or full-length human mHTT signiﬁcantly slowed the progression
of motor deﬁcits observed in the rotarod test [66].
Two recent studies suggested that SIRT1 prevents mHTT-induced
transcription decline by increasing the levels of brain-derived neuro-
trophic factor (BDNF) and the intracellular signaling pathways mediated
by its receptor, TrkB [47,66], which reduced expressionwas implicated in
HD striatal neurodegeneration [67]. Jeong and co-authors showed that
brain-speciﬁc knockout (KO) of SIRT1 resulted in exacerbation of brain
pathology, whereas OE of SIRT1 improved survival and expression of
BDNF in R6/2 mice [47]. Previous studies suggested that TORC1 (CREB-
regulated transcription coactivator 1) activated CREB-regulated tran-
scription by promoting the recruitment of transcriptional co-activators
to BDNF promoter. Authors showed that mHTT may affect TORC1–CREB
interaction, thus repressing BDNF transcription; contrariwise, SIRT1
deacetylates and activates TORC1 by promoting its interaction with
CREB [47] (Fig. 1).
If we consider SIRT1 as a factor involved in chromatin regulation,
constitutive SIRT1 OE may not always be beneﬁcial. Besides histone
deacetylation, SIRT1 canmodulate chromatin function throughmethyl-
ation of histones and DNA, forming repressive heterochromatin [40].
Moreover, SIRT1 antagonizes p300-mediated activation of FOXO3a
[68]. SIRT1 physically associate with and repressed p300 (through
deacetylation of K1020/K1024 residues), a histone acetyl transferase re-
lated to CBP that is impaired in HD and regulates numerous signaling
pathways by facilitating transcriptional activity of a broad array of tran-
scription factors [69,70] (Fig. 1). Indeed, this dual role of Sir2/SIRT1
on transcriptional activation may explain why 50% reduction of Sir2 ac-
tivity was shown to be neuroprotective in HD invertebrates typically
containing fewer neurons, arranged in less complex networks, than ver-
tebrate systems [58,59]. Importantly, most of the studies that achieved
neuroprotection through SIRT1 inhibition in more complex neuronal
systems used drug-like and non-selective inhibitors of SIRT1, calling
into question the direct effect of SIRT1 inhibition in HD models.
Clearly the role of SIRT1 in cellular protection is complex; however
the understanding of all pathways behind SIRT1 activation may answer
why the activation and partial reduction (but not complete deletion) of
Sir2/SIRT1 leads to the same phenotype in different HD models.
2.1. SIRT1-activating compounds in HD
Enhancing SIRT1 activity has been reported to increase lifespan in
several organisms; paradoxically, either SIRT1 activation or inhibition
has been found to exert neuroprotective properties though modulation
of diverse cascade pathways [59,66]. In light of this knowledge, both
SIRT1 activators and inhibitors are being actively explored. Resveratrol
(RESV), a naturally occurring polyphenolic SIRT-activating compound
(STAC) isolated from the skin of red grapes, was reported to be a potent,
but unselective, activator of SIRT1 in vitro, protecting against detrimen-
tal effects of high-fat diet exposure such as glucose intolerance, insulin
resistance or lifespan reduction [71]. A screen for molecule activators
for SIRT1 identiﬁed 21 different SIRT1-activating molecules, and the
most potent of which was RESV [72]. Although the legitimacy of
STACs as direct SIRT1 activators has been widely debated [73], in 2013
Sinclair's laboratory showed a mechanism of direct activation mediated
by an N-terminal activation domain in SIRT1 that is responsible for
some of the physiological effects of STACs [74]. Importantly, RESV has
the ability to activate important enzymes for energy and glucosehomeostasis such as AMPK and PGC-1α, increasingmitochondrial func-
tion [6,75] and so, it cannot be excluded that RESV might induce SIRT1
activation via other pathways that still remain to be identiﬁed. In fact,
RESV was identiﬁed as a phytoestrogen that binds and activates estro-
gen receptors and estrogen-related receptors (ERRs) [76]. Accordingly,
high doses of RESV can positively modulate the levels of ETC complexes
and oxygen consumption through ERRα activation, a master regulator
of mitochondrial ETC and biogenesis [77]. Remarkably, RESV stimulato-
ry effects on ETC did not involve SIRT1 activation, but rather estrogen re-
ceptor and ERRα [77]. Moreover, RESV, per se, is a powerful oxidant that
in a moderate to high μM range (N50 μM)was shown to activate AMPK
in a SIRT1-independentmanner, improvingmitochondrial function and,
consequently, neuronal survival [6] (Fig. 1). Likewise, RESV failed to im-
prove metabolic parameters and mitochondrial biogenesis in AMPKα1
subunit KOmice [78], revealing an important role of this kinase regulat-
ed under conditions favoring ATPmetabolism. Concordantly, high doses
of RESV improved neuronal survival in Sir2 homozygous null ﬂies ex-
pressing mHtt exon 1 with 93Q (Httex1pQ93) [58].
Over the last years we presented evidence that mitochondria and
metabolic deregulation plays a major role in HD pathogenesis. We
have shown that full-length (FL)-mHTT is associated with deﬁcits in
mitochondrial-dependent calcium handling and reducedmitochondrial
membrane potential (mmp) [79,80] that could be ameliorated by treat-
ment with Lys deacetylase (namely HDAC) inhibitors [79]. HD cybrids,
obtained after fusion of HD platelets with mitochondrial DNA-
depleted cells, showed decreased mmp when compared to control
cybrids [81], along with a reduction in mitochondrial levels of NADH/
NADt [31]. Recently, we also detected decreased brain energy changes
concomitantly with increased lactate/pyruvate ratio in a HD mice
model expressing human FL-mHTT with 128Q, the YAC128 transgenic
mice [82]. Energy deﬁcits have been largely associated with impaired
PGC-1α expression and/or function, which is regulated by SIRT1 [6,83,
84]. Indeed, PGC-1α is a highly versatile transcriptional co-activator
that interactswith a broad range of transcription factors involved in sev-
eral biological processes, including glucose and fatty acid metabolism,
mitochondrial biogenesis and oxidative phosphorylation [85]; there-
fore, PGC-1α has emerged as a common underlying cause of mitochon-
drial dysfunction in HD [86,87]. In NLS-N171-82Q transgenic HD mice
striatum, PGC-1α levels and their downstream transcription factors
nuclear respiratory factors -1 and -2 (NRF1, NRF2) and mitochondrial
transcription factor A (TFAM), andmitochondrial DNAwere signiﬁcant-
ly reduced [88]. Remarkably, RESV effects were associated with the in-
duction of genes for oxidative phosphorylation, including components
of the respiratory chain (e.g. NDUFB8), oxidative enzymes (e.g. CoxVa)
and ATPases (e.g. ATP5G3), which were explained by a RESV-mediated
PGC-1α deacetylation/activation by SIRT1 [75]. Furthermore, mHTT
also inhibits transcription of PGC-1α by interfering with the complex
CREB/TAF4 (transcription initiation factor TFIID subunit 4) acting on
the PGC-1α promoter [87]; in this respect, an oral dosing by gavage of
RESV of 25 mg/mouse/day, 5 days per week, for 45 days, was able to
rescue PGC-1α and NRF-1 mRNA expression in peripheral tissues of
N171-82Q HD transgenic mice as a consequence of its deacetylation
by SIRT1 [89] (Fig. 1). Indeed, it was shown previously that muscle
ﬁbers of RESV-treated mice presented increased mitochondrial size
and density, mitochondrial DNA content and higher maximum oxygen
consumption and citrate synthase activity, suggesting an increased oxi-
dative capacity [75]; however, the treatment failed to improve motor
deﬁcits, survival or striatal atrophy associated with the HD phenotype
[89]. The authors explained these negative results with the inefﬁcacy
of RESV in the central nervous system (CNS), since the treatment did
not improve transcriptional response in the striatum, when compared
with peripheral tissues [89]. However, previous studies showed that
orally administered RESV could cross the blood–brain barrier and
accumulate in the cerebral cortex, but not in the striatum or hippocam-
pus [90]. Conversely, we observed that continuous intracutaneous
administration of 1 mg/kg/day of RESV (a signiﬁcant lower dose than
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acetylation (H3K9) in both cortex and striatum of 9 month-old YAC128
mice, with signiﬁcant improvement of motor coordination [Naia et al.,
unpublished data]. Importantly, the efﬁcacy of low doses of RESV (e.g.
0.2–1mg per bodyweight, daily) was observed despite its low bioavail-
ability, as a consequence of its poor aqueous solubility and rapidmetab-
olism, suggesting that even the concentration of RESV obtained from
dietary sources, such as red wine, could be therapeutic.
More recently several synthetic molecules with the same enzymatic
mechanism as RESV, but structurally unrelated, were reported, such as
SRT1720, SRT2183 and SRT2104. These molecules were described to
be 1000 timesmore potent than RESV [91], recapitulating the beneﬁcial
effects in mice fed high-fat diet and other diabetic model systems [92,
93], with improved selectivity for SIRT1 and well tolerated in healthy
volunteers [94]. Indeed, diet-administrated 0.5% SRT2104 was able to
pass through the blood–brain barrier of N171-82Q HD transgenic
mice, improving motor function, attenuating neocortical atrophy and
extendingmedian lifespan by about 16%, compared to HDmice subject-
ed to control diet [95]. Importantly, similarly as RESV, SRT2104 im-
proved whole-body metabolism, increasing mitochondrial content and
mouse survival [75,93]. These studies revealed that interventions
aimed towards a more selective pharmacological modulation of SIRT1
activity could represent an attractive approach for delaying HD onset.
Besides RESV-like compounds, themost direct way to activate SIRT1
would be to raise intracellular NAD+ levels. β-Lapachone (β-lap), orig-
inally isolated from bark of South America Lapacho tree, is a substrate
of NADH-quinone oxidoreductase and has been shown to stimulate
NADH oxidation [96]. In human SH-SY5Y cells transfected with HTT-
exon1(97Q), β-lap increased SIRT1 activity, as shown by increased
deacetylation of SIRT1 substrates (such as PARP-1 and the Autophagy
protein 5, Atg5) and the nuclear translocation of FOXO1, consequently
reducing polyQ aggregates and cell toxicity. Moreover, a signiﬁcant
increase in cytotoxicitywas observed inHD cells lacking SIRT1 but incu-
bated with β-lap [97].
2.2. SIRT1-inhibiting compounds in HD
The existent SIRT1 inhibitors so far exhibit low potency and unat-
tractive pharmacological and biopharmaceutical properties. Moreover,
their inhibitory activity may be questionable. All SIRTs require NAD+
as an essential cofactor and, as described before, nicotinamide (NAM)
is predominantly used for NAD+ biosynthesis in mammals and has
been identiﬁed as an end-product inhibitor of SIRT1 [98]. Recently, a
quantitative mass spectrometry assay showed that NAM effects are in-
deed primarily mediated by SIRT1 inhibition, since the acetylome
changes of SIRT2-/- and SIRT6-/- cells correlated weakly with NAM-
induced changes, compared to SIRT1-/- cells [99]. However, there are un-
certain observations regarding the metabolic effects of NAM, since it
modulates the sirtuin system in a complex way. NAM inhibits SIRT1 ac-
tivity through non-competitive binding, which promotes a base-
exchange reaction at the expense of deacetylation [100], and/or com-
petitively binds at the SIRT1 conserved pocket that participates in
NAD+ binding and catalysis [101]. Conversely, NAM offers multiple
protectivemechanisms as a positive NAD+donor, preventingNAD+de-
pletion and protecting neurons against excitotoxicity [102]. Indeed,
prolonged administration of high doses of NAM can increase SIRT1
mRNA expression and its enzymatic activity [103]. Concordantly, treat-
ment with 250 mg/kg/day NAM for 12 weeks in B6.HD6/1 mice in-
creased both mRNA and protein expression of BDNF and PGC-1α,
concomitantly with reduction of PGC-1α acetylated levels, improving
motor deﬁcits tested by open ﬁeld, rotarod and balance beam activities.
Still, the improvement in motor function was not accompanied by a re-
duction in mHTT aggregation [51]. Although retaining SIRT1 protein
levels, in this study NAM seems to serve as a SIRT1 activator by increas-
ing NAD+ levels, since it increased deacetylation of PGC-1α and, proba-
bly, TORC1, which in turn activates BDNF transcription [51].During the last years, a large number of SIRT1 inhibitors have been
identiﬁed by in silico screenings and, although they have low afﬁnity for
SIRT3 and SIRT5,most of them alsomodulate SIRT2 activity [104]. Sirtinol
is awell-knownSIRT inhibitorwhich inhibits human SIRT1with an inhib-
itory constant (IC)50 of 131 mM, 3.25-fold higher than for SIRT2 (IC50 =
40 mM) [105]. However, a very recent acetylation-screening assay
showed that the fraction of downregulated acetylation sites in sirtinol-
treated cells was greater than the fraction of upregulated sites. Moreover,
NAM upregulated 12% of acetylation sites, whereas sirtinol affected less
than 2% of sites, indicating that the scope of these inhibitors is vastly dif-
ferent [99]. Studies with this inhibitor support the concept that pharma-
cological activation of SIRT1 alleviates polyQ-dependent aggregation.
Sirtinol treatment for 12 h abolished pro-autophagic activity in human
cells expressing HTTEx1(97Q), increasing mHTT aggregation [97].
More recently, a pharmacological compounddescribed as being a highly
selective inhibitor of Drosophila Sir2 and mammalian SIRT1 named
selisistat was described. Notably, Htt-challenged ﬂies treated with
selisistat displayed a concentration-dependent (in μM range) rescue
of photoreceptor neurons and extended lifespan with the greatest per-
centage of survival achieved in 10–20 days [59]. Furthermore, selisistat,
which has proven to be safe in healthy human volunteers, is currently
being tested in HD phase I clinical trials [105; http://clinicaltrials.gov,
NCT01485965 and NCT01485952]. Importantly, no obvious effects of
short-term daily doses of 10 or 100 mg selisistat were observed in
terms of soluble HTT levels in HD patients [106]. Besides, the role of
selisistat as selective Sir2/SIRT1 inhibitor is debatable. Smith and co-
authors [59] assessed the speciﬁcity and activity of selisistat on Sir2/
SIRT1 by observing decreased levels of acetylated p65 (at K310; a de-
scribed SIRT1 substrate) in SIRT1 and Sir2 transfected cells [59,107].
However, there are evidences that p65 is also deacetylated by SIRT2 in
the cytoplasm in the same Lys residue [108]. Therefore, the question
that remains open is: Can selisistat also modulate SIRT2 deacetylase
activity (Section 3), which in turn appears to be deleterious in HD
models?
Many questions remain unanswered regarding the role of SIRT1 in-
hibitors in HD. So far, the lack of structural information has hindered
the use of modern drug design methods in the search for highly selec-
tive SIRT1 inhibitors that have no inﬂuence on other family members,
especially SIRT2. Additionally, the effort in ﬁnding pharmacological
modulators has always been more prominent for activators, since
there ismore convincing data supporting its beneﬁcial effects. However,
more effective and selective SIRT1 inhibitors need to be generated, as
well as their speciﬁcity improved at the level of individual acetylation
sites, which is critical for understanding the distinct modes of action
and to demystify the exact role of SIRT1 in neuronal survival and
lifespan in health and disease.
3. SIRT2 and HD
SIRT2 is strongly expressed in both CNS and peripheral nervous
system [109]. It is primarily cytosolic, where it deacetylates the major
component of the microtubules, α-tubulin at Lys 40 [109,110], but
may also occur in the nucleus where it preferentially deacetylates his-
tones H3K56 and H4K16 and functions as a mitotic checkpoint protein
allowing damage cells to proceed to apoptosis [111–115]. Initial studies
inHSP2, the SIRT2ortholog in yeast, showed that it is upregulated by CR,
extending lifespan by a Sir2-independent mechanism [116]; however
more recent data point to an opposite role on neuroprotection. Recent
reports demonstrated an association betweenα-tubulin acetyltransfer-
ase activity and neurodegenerative diseases [117–119]; in fact there is
an age-dependent accumulation of SIRT2 microtubule deacetylation in
the mouse brain and spinal cord [110]. This posttranslational modiﬁca-
tion prevents the recruitment of kinesin-1 and dynein/dynactin motor
complexes to microtubules, disrupting anterograde and retrograde
transport, which is reduced in HD brains [120,121]. The abnormal
interaction between pathogenic polyQ proteins and components of
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dria) along axons, ultimately leading to synaptic starvation and cell
death [122]. Importantly, HDAC6 rivals with SIRT2 to deacetylate
α-tubulin and its inhibition appears to compensate transport deﬁcits
in HD cells, revealing that SIRT2 may be a relevant target to counteract
dysfunctional intracellular transport [121,123].
With regard toHD, Luthi-Carter and co-workers (2010) demonstrat-
ed that genetic ablation of SIRT2 rescued photoreceptor neurons death
in a dose-dependent manner in Httex1pQ93 adult ﬂies [124]. These re-
sultswere also conﬁrmed by Pallos et al. [58]. Moreover, primary striatal
neurons overexpressingwild-type SIRT2 abolished the neuroprotection
achieved by the SIRT2 pharmacological inhibition; likewise, the expres-
sion of a dominant-negative deacetylase deﬁcient SIRT2 mutant dimin-
ished SIRT2 activity, reducing the number of mHTT inclusions [124].
Nevertheless, SIRT2 levels were not up-regulated in HD models [23,
124] and the constitutive genetic inhibition of SIRT2 did not modify
disease progression in the R6/2mousemodel [125]. Indeed, the authors
did not conﬁrm the effectiveness of SIRT2 reduction or abolition since
the primary targets of SIRT2, α-tubulin and histone H4, were not
found hyperacetylated in both R6/2 mice heterozygous and KO for
SIRT2, respectively [125].
3.1. SIRT2-inhibiting compounds in HD
Several SIRT2 inhibitors were discovered in the last few years and
the efﬁcacy of the sulfobenzoic acid derivatives AK-1 (IC50 = 12.5 μM)
and AK-7 (IC50 = 15.5 μM) in neurodegenerative diseases has been de-
scribed [23,124,126,127]. Two structurally different and selective SIRT2
inhibitors, AGK2 and AK-1, were used to evaluate their disease-rescuing
effects in Drosophila melanogaster and C. elegans expressing N-terminal
exon1 Htt fragments. Both inhibitors, at a lower μM dose, promoted
signiﬁcant neuroprotection in HD ﬂies and worms, improving the num-
ber of photoreceptor and touch receptor neurons, respectively [124].
Importantly, the authors concluded that SIRT2 inhibition promotes
neuroprotection by decreasing lipid and sterol biosynthesis in both
HD eukaryotic cells and in Drosophila models [124] (Table 1, Fig. 2).Fig. 2. SIRT2 inhibition counteracts HD-related cholesterol metabolism deregulation. SIRT2may
synthesis of cholesterol, which is accumulated in HD cells. Speciﬁc SIRT2 inhibitors AK-1/7 de
cholesterol levels in cells expressing mHTT. Abbreviations: ac, acetyl group; mHTT, mutant huChanges in cellular cholesterol metabolism have been shown to
be detrimental and linked to neurodegeneration in HD [128,129].
In 2002, it was described that clonal striatal-derived cells expressing
different N-terminal 548-amino-acid HTT fragments (retaining 67Q,
105Q and 118Q) exhibited reduced expression of genes involved in cho-
lesterol and fatty acid biosynthesis [130]. Further studies conﬁrmed the
transcriptional deregulation of cholesterogenic genes and decreased
sterol content in the striatum and cortex of R6/2 mice [131]. Neverthe-
less, contrasting data revealed cholesterol accumulation in YAC72 HD
mice brain [132]. Although reduced expression of cholesterogenic
genes has been observed in post-mortem caudate samples from HD
patients, grade IVHDpatients showed an increase in sterol levels in cau-
date post-mortem tissue [131,132], indicating that cholesterogenic
gene expression might be decreased in HD models as a consequence
of cholesterol accumulation. Accordingly, SIRT2 inhibition with AK-1
blocked nuclear translocation of sterol response element (SRE) binding
protein 2 (SREBP-2), a transcription factor that up-regulates the synthe-
sis of cholesterol, downregulating cholesterol biosynthesis and, in turn,
reducing mHTT toxicity [124] (Fig. 2). However, in a more recently re-
port, SIRT2 inhibition did not modify cholesterol synthesis pathway,
neither in SIRT2 KO mice, nor in acute-treated mice with the SIRT2
inhibitor [S]-35 [125].
In 2011, the AK-7 was demonstrated to be brain-permeable and
more selective to SIRT2 (at least 50% inhibition) compared to SIRT1 or
SIRT3 (25% inhibition) [133]. Chronic administration of 10–20 mg/kg
AK-7 twice a day resulted in improved motor function and reduced
polyQ aggregation in R6/2 and knock-in HDmicewith 140 CAG repeats,
whichmanifest a severe andmild neurological phenotype, respectively.
Moreover, morphometric analysis showed a signiﬁcant improvement in
striatal neuronal volume in AK-7-treated R6/2mice, concomitantlywith
increased survival by about 13.2% [23].
Altogether, these two important studies suggest a novel and
attractive role of SIRT2 inhibition in the regulation of HD neuronal
metabolism, speciﬁcally cholesterol biosynthesis, culminating in
a marked reduction of mHTT aggregation, which should be further
investigated.increase the deacetylation and translocation of SREBP-2 to the nucleus, increasing the bio-
creased SREBP-2 translocation to the nucleus, as depicted by the red crosses, normalizing
ntingtin; SIRT2, sirtuin 2; SRE, sterol response element; SREBP-2, SRE binding protein 2.
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SIRT3 research in HDboils down to one publication so far, by Fu et al.
[134]. As has often been pointed out, mitochondrial dysfunction is a
hallmark of HD [135] and, therefore, a relevant role for SIRT3 in HD
must be hypothesized. SIRT3 provides a unique tool to understand mi-
tochondrial metabolism since it is the greatest regulator of the global
acetylation landscape of mitochondrial proteins and, like SIRT1, it is
highly expressed in kidney, brain andheart [136]. Remarkably, although
nuclear protein acetylation patterns are dramatically altered in HD cells
[42], there is no study showing that this pattern also occurs in HDmito-
chondria. A quantitative mass spectrometry method in wild-type mice
versus SIRT3−/−mice or in wild-typemurine embryonic ﬁbroblasts ver-
sus SIRT3 KO cells revealed multiple proteins regulated by acetylation,
often at multiple sites, across several pathways, including fatty acid ox-
idation, ketogenesis, amino acid catabolism and urea and tricarboxylic
acid cycles [137–140]. The hyperacetylation results in dysfunction
of these proteins, eventually leading to mitochondrial dysfunction. In-
deed, the most acetylated protein was the highly abundant urea cycle
enzyme carbamoyl phosphate synthase 1 (CPS1)with 70 of 97 Lys acet-
ylated. Moreover, SIRT3-dependent deacetylation was also observed in
isocitrate dehydrogenase 2 (IDH2) at K360 and in glutamate dehydro-
genase (GDH) at K527; the superoxide dismutase 2 (SOD2), a protein
involved in reactive oxygen species (ROS) dismutation through conver-
sion of superoxide anion into hydrogen peroxide, was also found to be
acetylated in three different Lys sites (K53, K68 and K89) [137–139,
141,142] (Fig. 3). Importantly, acetylation of SOD2 at K68 was reported
to decrease its activity [142]. Interestingly, we found decreased
acetylated-K68 SOD2 levels in HD striatal cells expressing 111Q, in
agreement with increased SOD2 activity, suggesting a compensatory
mechanism against higher levels of ROS [143]. Nonetheless, in the
same striatal cells ε-viniferin treatment, a resveratrol dimer, but notFig. 3. SIRT3 controls mitochondrial dysfunction induced by mHTT. Upon activation with
ε-viniferin, SIRT3 deacetylates and activates SOD2, promoting resistance to oxidative
stress, and LKB1, increasing mitochondrial biogenesis in a AMPK-dependent manner,
thus counteractingmitochondrial impairment induced bymHTT. Abbreviations: ac, acetyl
group; LKB1, liver kinase B1; mHTT, mutant huntingtin; ROS, reactive oxygen species;
SIRT3, sirtuin 3; SOD2, superoxide dismutase 2.resveratrol itself, was able to signiﬁcantly increase SIRT3 expression
and decrease ROS production through SOD2 deacetylation/activation
[134,138] (Fig. 3). Interestingly, cells expressing mHTT and subjected
to cellular stress following serum deprivation displayed reduced SIRT3
levels that were reset after ε-viniferin treatment [134]. Apparently, ε-
viniferin activates AMPK in a SIRT3-dependent manner, through
deacetylation of the primary upstream AMPK kinase, liver kinase
B1 (LKB1, also known as serine/threonine kinase 11— STK11), enhanc-
ing PGC-1α levels and, consequently, mitochondrial biogenesis and
preventing the loss of mmp and NAD+/NADH ratio in HD cells [134]
(Fig. 3).
Previous we observed that bioenergetic dysfunction in HD human
cybrids and mice striatal cells was associated with decreased pyruvate
dehydrogenase (PDH) activity, protein levels and increased phosphory-
lation/inactivation of E1alpha subunit (PDHA1α) [31,144]. Moreover,
PDH was also shown to be impaired in HD human brains [145] and
dichloroacetate (PDH activator) showed protective effects in HD
mousemodels [146], placing PDH in the center of theHD-associatedmi-
tochondrial dysfunction. Recently, SIRT3was discovered as an upstream
deacetylase of PDHA1 and pyruvate dehydrogenase phosphatase 1
(PDP1), two major components of PDH complex [147,148]. In this
work, the authors showed that H1299 cells with stable knockdown
(KD) of SIRT3, but not the SIRT5, had increased acetylated levels of
PDHA1 and PDP1, which facilitates PDHA1 phosphorylation, leading to
decreased PDH ﬂux rate in isolated mitochondria. Conversely, treat-
ment with recombinant SIRT3 resulted in decreased K321 and K202
acetylation of PDHA1 and PDP1, respectively [148]. Together, we can
anticipate that SIRT3 activationmaymodulate PDH activity in HDpossi-
bly through deacetylation of important components of PDH complex.
Still with regard to bioenergetic dysfunction, SIRT3 also deacetylates
components of complexes I, II and V [149–151], indicating a role in reg-
ulation of oxidative phosphorylation machinery and ATP production,
that was found to be impaired in several HDmodels and in postmortem
brain tissues from HD cases with substantial neuronal loss [152,153]. In
mice, complex I is composed by more than 40 distinct proteins that to-
gether function as NADH dehydrogenase; SIRT3 can physically interact
and deacetylate at least one of the complex subunits, the 39 kDa protein
NDUFA9, inwhichK370 is acetylated. Interestingly, complex I inhibition
with either rotenone or hydrogen peroxide can lead to the dissociation
of the SIRT3-complex I interaction, reducingmore than 50% of basal ATP
levels in the heart, kidney and liver [149]. Moreover, the ﬂavoprotein
subunit of succinate dehydrogenase was previously identiﬁed as having
a total of 13 acetylated Lys, six of which (K182, K250, K480, K550, K624
and K633) increased in SIRT3 KO mice [149].
Recently reports have questioned the distribution of SIRT3 limited to
mitochondria. This uncertainty arises from the two different isoforms
(a ~28 kDa processed/short and a ~44 kDa full-length, FL) of SIRT3,
which are expressed in both humans and mice and appear to be differ-
entially distributed [154]. Indeed, it was shown that FL-SIRT3 localizes
and functions in the nucleus [155,156]; however, its role in this organ-
elle remains controversial. In the nucleus, FL-SIRT3 was shown to
deacetylate histone H3K9 and H4K16 in vivo, repressing transcription
in a gene-speciﬁc manner when recruited to its promoter [155]; also
the non-global hyperacetylation of SIRT3 KD suggests that this action
occurs in speciﬁc regions of the genome. Conversely, it has been
shown that FL-SIRT3 is able to deacetylate particular targets in the nu-
cleus of cardiomyocytes such as FOXO1 [157], elevating the expression
of FOXO1 target genes, catalase and SOD2, while decreasing senescence
phenotypes; SIRT3 also deacetylates Ku70 increasing its activity and
hindering apoptotic signals [158]. SIRT3 can also be translocated from
the nucleus to themitochondria upon cellular stress, such as DNA dam-
age induced by etoposide and UV-irradiation [155]. Although there are
no previous studies of nuclear SIRT3 in neurons, Fu and collaborators
[134] showed that ε-viniferin treatment attenuates mHTT-mediated
decline of PGC-1α. Inversely, PGC-1α strongly stimulates SIRT3 gene
expression on SIRT3 promoter through ERRα co-activation, and the
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detoxifying enzymes and several components of the respiratory chain
[159].
The beneﬁcial effect of SIRT3 in regulating bioenergetics and activat-
ing antioxidant defense system is apparent; however its role in HD
neuroprotection remains vague. Although the ﬁrst evidence point to a
protective role of SIRT3 activation on energy metabolism homeostasis,
thereby protecting cells from mHTT toxicity, further studies using ge-
netic modulation and animal models needed to be performed. Firstly,
SIRT3 mitochondrial protein levels and activity in distinct HD models
must be clariﬁed, since SOD2 deacetylation/activation were found to be
increased in HD striatal cells [143], suggesting higher SIRT3 activity in
HD mitochondria. Interestingly, SIRT3 mRNA and protein levels were
found signiﬁcantly increased in temporal neocortex from Alzheimer's
disease patients [160], a neurodegenerative disorder that shares several
common molecular mechanisms with HD, including generation of free
radicals. Thus, novel agents that are able to selectivelymodulate SIRT3 ac-
tivitymight be of great therapeutic value, providingmeans for enhancing
neuroprotection.5. Conclusion and perspectives
HD is a complex genetic neurodegenerative disorder with many
underlying dysfunctional pathways, while SIRTs are molecules with
numerous cell targets that appear to have a relevant role in HD patho-
genesis. In the current article several substrates are described to be
activated or inhibited by SIRTs, which in turn are important for the func-
tionality of vital cellularmechanisms, such as transcription regulation or
energy production. The role of Sir2/SIRT1 on HD neuroprotection is still
highly controversial. Indeed, it seems confusing that both inhibition and
activation of a single enzyme (SIRT1) may lead to neuroprotection.
SIRT1-dependent deacetylation can enhance the activity of speciﬁc
targets and, at the same time, can repress global transcription, which
is already severely affected in HD. As an example, SIRT1 is capable of
activating FOXO3a [66], a pro-survival transcription factor, however it
also deacetylates and inactivates the key chromatin-modifying protein
p300 [70]. Nevertheless, there is now overwhelming evidence that
SIRT1 activation counteracts neuronal death in numerous in vitro and
in vivoHDmodels. Moreover, the protective effects of its partial deletion
occur in lower eukaryotes. In mammals, compounds that inactivate
both SIRT1 and SIRT2 appear to have antagonist roles on neuronal
survival. With that in mind, several studies in HD have resorted to the
use of pharmacological modulators that are not selective for a certain
SIRT. Many of the effects of STACs (e.g. resveratrol) overlap with those
triggered by SIRT1 overexpression; however these small molecules
have been involved in several pathways, making difﬁcult to know
whether the observed effects are due to SIRT1 activation. Moreover,
smallmolecule inhibitors exhibit lowpotency and unattractive biophar-
maceutical properties. Thus, it is currently a challenge to develop strong
and selective activators/inhibitors, as they would bring considerable
beneﬁts for the future therapeutic interventions in HD and other neuro-
degenerative diseases. Additionally, it is essential to pursue the research
on SIRTs genetic modulation, particularly for SIRT3 that remains largely
unexplored.
Notably, SIRT4–7 also mediate physiological effects linked to health
beneﬁts and thus it is important to expand the studies on their
function(s) in HD. As mentioned before in this review, PDH complex
plays an important role in HD bioenergetics and, recently, SIRT3 was
proven to deacetylate crucial subunits of this complex, which result in
more active PDH. Importantly, a new study revealed that SIRT4 also
regulates PDH complex in an opposite way. SIRT4 enzymatically hydro-
lyses lipoamide cofactors from the E2 component of PDH, diminishing
PDH complex activity [161], making it an interesting target for inhibi-
tion. Contrariwise, SIRT6 activation may reduce the expression of PDH
kinases, which phosphorylate and inactivate PDH and seem to beincreased in HD cells [31,144,162], thereby enhancing PDH activity
and metabolic function in HD-affected cells.
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